Lilly's Basaglar Becomes A Blockbuster
Global Sales Of Follow-On Insulin Glargine Grow By Two-Fifths In 2019
Quarterly global Basaglar sales rose above $300m for the first time in the fourth quarter of 2019, with full-year turnover pushing the insulin glargine hybrid well into blockbuster territory.
Stay ahead of every shift in generics and biosimilars.
More from Earnings
- • By
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
- • By
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
- • By
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
More from Business
- • By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
- • By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
